Dishman Carbogen Amcis Ltd Q4 FY2023 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/399xsqkjf8v4xcfzjgfsur2h.pdf

Key Takeaways


The Inflection Point: CAPEX Cycle Ends, Commercialization Begins

Sanjay Majmudar: "I think we are at the inflection point, almost everything that should have been corrected has been put in place. France is ready to go. The co-investment project will be commercialized."

Regulatory Catalysts: EDQM and PMDA

Arpit Vyas: "They have been extremely impressed and many of them have decided to take a risk and start ordering looking at the facilities and the quality of the talent that has been seen during the audit."

Q4 FY23 Margin Dissection: One-Off Cost Spikes


Operational Excellence: Site-by-Site Progress

Arpit Vyas: "I have seen quite a few warehouses across the globe. And trust me when I say that what has been created is truly something unseen at least in our industry."

Balance Sheet and Capital Allocation

Arpit Vyas: "In our business, as a company, we like to use debt as a financial tool rather than use our own cash flows that we would like to invest."

Guidance & Commitments

CommitmentSpecificsTimeline
Return to positive profit territoryConfident of coming into positive profit territory in the current fiscal yearFY24
EBITDA margin recoveryMove back to 25–26% EBITDA margin (achieved in FY19–20)FY25–26
Revenue CAGRAt least 12–15% CAGR over the next 5 years5-year horizon
Bavla full productionNear-full production of all 8 or 9 units, with revenue much higher than FY23FY24
EDQM inspectionExpected any time between now and December, per management's calculated assumptionH2 CY23
PMDA auditConfirmed for 1st to 4th AugustAugust 2023
French facility operationsFinal qualification grant about to start; operations expected to beginFY24
Swiss co-investment revenueConfident of generating some revenueFY24
CAPEX run rateCHF 3.5–4 crore consolidatedFY24
Maintenance + growth CAPEXRoughly EUR 40 million a fair figure going forwardOngoing
Free cash flowNot expected to remain negativeGoing forward
Related-party loan repaymentPlan to clear before completion of the fiscal yearFY24
SAP/HANA ERP implementationTarget to implement new ERPQ1 FY24

Key Metrics

MetricQ4 FY23
Net revenue₹618.6 cr, compared to ₹569 cr in Q4 FY22
Full-year FY23 revenue₹2,413 cr, growth of almost 12% over FY22
Adjusted EBITDA₹83 cr, compared to ₹77 cr in Q4 FY22; adjusted for mark-to-market FOREX losses, SaaS IT costs, and nonrecurring expenses
Full-year FY23 adjusted EBITDA₹414 cr, compared to ₹390 cr in FY22
Full-year FY23 adjusted EBITDA margin17.2%, compared to 18.2% in FY22; energy costs increased by almost ₹18.5 cr
Reported EBITDA₹51 cr, compared to ₹22 cr in Q4 FY22
COGS as a percentage of revenue29% for Q4 FY23, higher than the full-year average of roughly 20% to 21% due to commercial supplies mix and higher cholesterol raw material costs
Other expenses₹132 cr, a decline of about 10% from ₹147 cr in Q4 FY22; includes mark-to-market FOREX loss of about ₹16.5 cr
Full-year mark-to-market FOREX loss₹50 cr
Exceptional items₹45.6 cr (about CHF 0.54 cr), impairment of design and engineering costs for a greenfield project put on hold
Full-year additional provision for onerous contracts₹42 cr net addition, outstanding provision as of March 31, 2023 roughly ₹55 cr
One-time R&D and consultancy expenses₹4.2 cr, for Vitamin D project with Boston University and nonrecurring consultancy
Net debt (excluding liabilities)CHF 15.9 cr as of March 31, 2023
Full-year capital expenditure$69 million
Carbogen Amcis total turnover (FY23)CHF 24.4 cr, 12% increase on target
Gross debt₹1,800 cr, 80% to 90% denominated in Swiss francs; interest cost roughly 4% to 4.5% on average
Bavla Q4 revenue run-rate₹70 cr